Safe Save Medical Cell Sciences & Technology Co.,Ltd.   Report issue

For profit Phase 3
Founded: Zhubei City Taiwan (2011)

Organization Overview

First Clinical Trial
2019
NCT04277221
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Safe Save Medical Cell Sciences & Technology Co.,Ltd.

Active Ingredients

Drugs in Phase 3 Trials (1)

autologous dendritic cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glioblastoma (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1